Battle Card: Qpex Biopharma Sales Trigger
New Qpex President Gareth Morgan sparks a pipeline boost. Scale R&D trials, streamline partnerships. Pitch portfolio software & collab tools. Next touch: LinkedIn connect.
Published on
Do not index
Do not index
🚀 Battle Card: Qpex Biopharma, Inc.
Quick trigger:
👤 Decision Maker in the News
- Gareth Morgan, President · 🔗 LinkedIn
💡 Why It Matters
- Qpex Biopharma, Inc. sales trigger signals a push for deeper anti-infective R&D and stronger public-private partnerships under new leadership. → Source
🎯 Core Pain Point
- Scaling global R&D capabilities to advance xeruborbactam into late-stage trials
- Managing complex partnerships with governments and NGOs for antibiotic access
💰 What to Pitch
- Primary: Portfolio Management Software → Streamline oversight across clinical and regulatory teams
- Expansion: Digital Collaboration Platform → Accelerate co-development with public-private partners
🗺️ Quick Context
- HQ: San Diego, CA
- Employees: ≈ 80
- Rev: ≈ $25 M
- Website: qpexbio.com
🤼 Competitive Intel
*Which other vendors you’ll probably face to win **Qpex Biopharma, Inc.*’s business.
- Veeva Systems — R&D Suite
- Unique edge: Integrated CTMS, eTMF, regulatory in one platform
- Evaluated by VP R&D for cross-functional visibility
- Medidata Solutions — CTMS & Data Analytics
- Unique edge: Advanced biostatistics and real-world evidence tools
- Evaluated by Head of Clinical Ops for trial acceleration
- Oracle Health Sciences — CTMS / eTMF
- Unique edge: Scalability for global registrational studies
- Evaluated by Dir. Regulatory Affairs for compliance depth
- Benchling — R&D Informatics
- Unique edge: Lab notebook + molecular data integration
- Evaluated by SVP Portfolio Mgmt for discovery workflow
✅ Do-Now Checklist for this Qpex Biopharma, Inc. sales trigger
Connect with Gareth Morgan on LinkedIn (link above)
Generate personalized email & DM referencing his anti-infective leadership vision
Log next actions in CRM: follow up Day 3 & Day 10
Next Step
Get this intel daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑<1-line value>❑
PROOF_METRIC = ❑<metric>❑
CTA_STYLE = ❑quick_call | case_study❑
TONE = ❑friendly | punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Gareth
COMPANY = Qpex Biopharma, Inc.
DEPT = R&D
SIZE = ≈80
BOTTLENECK = scaling global R&D capabilities
EVENT = Gareth Morgan Named President
DETAIL = your appointment as President
PAIN = scaling global R&D capabilities to advance xeruborbactam into late-stage trials
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251015554749&div=41152219
SIM_CO = Shionogi
WIN_METRIC = ≈TBD
NEXT_SIZE = ≈150
EMP_EST = ≈80
REV_EST = ≈25M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈80-person R&D
Gareth—noticed your R&D team is ≈80.
That’s when scaling global R&D capabilities slows growth.
We helped Shionogi fix this with ≈ TBD.
Result: ≈TBD.
Quick call?
PS—next bottleneck hits ≈150.
DM ≤45 words, TONE:
Saw your post about your appointment as President — scaling global R&D capabilities to advance xeruborbactam into late-stage trials.
≈ TBD. ≈ TBD.
Quick chat?